Oryzon Genomics S.A.
ORYZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $101,293 | $97,487 | $128,228 | $150,795 |
| - Cash | $5,619 | $12,257 | $21,317 | $28,725 |
| + Debt | $11,203 | $13,687 | $17,441 | $13,771 |
| Enterprise Value | $106,878 | $98,918 | $124,352 | $135,841 |
| Revenue | $7,359 | $14,192 | $15,698 | $10,615 |
| % Growth | -48.1% | -9.6% | 47.9% | – |
| Gross Profit | $7,057 | $13,948 | $15,234 | $9,869 |
| % Margin | 95.9% | 98.3% | 97% | 93% |
| EBITDA | -$4,376 | -$4,433 | -$5,350 | -$6,880 |
| % Margin | -59.5% | -31.2% | -34.1% | -64.8% |
| Net Income | -$3,665 | -$3,353 | -$4,231 | -$4,687 |
| % Margin | -49.8% | -23.6% | -27% | -44.2% |
| EPS Diluted | -0.057 | -0.055 | -0.076 | -0.089 |
| % Growth | -2.7% | 27% | 15% | – |
| Operating Cash Flow | -$5,690 | -$575 | -$1,848 | -$3,626 |
| Capital Expenditures | -$7,710 | -$14,503 | -$14,271 | -$11,761 |
| Free Cash Flow | -$13,399 | -$15,078 | -$16,118 | -$15,388 |